NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis $1.05 0.00 (0.00%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.03 -0.02 (-1.52%) As of 09/23/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About BioCardia Stock (NASDAQ:BCDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioCardia alerts:Sign Up Key Stats Today's Range$1.03▼$1.0850-Day Range$0.77▼$1.2552-Week Range$0.75▼$1.80Volume140,886 shsAverage Volume367,903 shsMarket Capitalization$15.90 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview BioCardia, Inc. is a biotechnology company developing regenerative medicine therapies for cardiovascular diseases. The company focuses on cell-based treatments intended to repair or improve damaged heart tissue and restore cardiac function in patients with serious cardiovascular conditions. BioCardia’s portfolio includes the investigational CardiAMP Cell Therapy System, which uses a patient’s own bone marrow-derived cells and is being evaluated for conditions such as ischemic heart failure and chronic myocardial ischemia. The company also develops CardiALLO, an investigational allogeneic cell therapy based on donor-derived cells. Its technologies include cell-processing, patient-selection, and catheter-based delivery systems designed to support the administration of regenerative therapies to the heart. BioCardia’s products remain in clinical development and are being evaluated through clinical trials rather than marketed as broadly approved treatments. The company is headquartered in Sunnyvale, California, and serves the cardiovascular research and clinical markets through its development programs and relationships with medical institutions. Peter Altman has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More BioCardia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreBCDA MarketRank™: BioCardia scored higher than 71% of companies evaluated by MarketBeat, and ranked 346th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingBioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialBioCardia has a consensus price target of $25.00, representing about 2,281.0% upside from its current price of $1.05.Amount of Analyst CoverageBioCardia has only been the subject of 3 research reports in the past 90 days.Read more about BioCardia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioCardia has a P/B Ratio of 13.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BioCardia's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.06% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in BioCardia has recently decreased by 2.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentBioCardia has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioCardia this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for BCDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $24,956.00 in company stock, which represents 0.1570% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,956.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20.57% of the stock of BioCardia is held by institutions.Read more about BioCardia's insider trading history. Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCDA Stock News HeadlinesBioCardia Provides Update on Near-Term Regulatory and Clinical Milestones for CardiAMP and Helix PlatformsSeptember 23 at 9:31 AM | quiverquant.comQBioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin SubmissionSeptember 23 at 9:15 AM | globenewswire.comHas Dylan Jovine lost his mind?SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation. But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly. An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151. | Behind the Markets (Ad)BioCardia Inc.September 22 at 1:32 PM | money.usnews.comBioCardia to Present CardiAMP, Helix and Heart3D Progress at H.C. Wainwright Global Investment ConferenceSeptember 10, 2026 | quiverquant.comQBioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | globenewswire.comBioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for ApprovalAugust 24, 2026 | globenewswire.comBioCardia (BCDA) Q2 2026 Earnings Call TranscriptAugust 20, 2026 | finance.yahoo.comSee More Headlines BCDA Stock Analysis - Frequently Asked Questions How have BCDA shares performed this year? BioCardia's stock was trading at $1.25 at the beginning of the year. Since then, BCDA shares have decreased by 16.0% and is now trading at $1.05. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. Read the conference call transcript. When did BioCardia's stock split? BioCardia's stock reverse split on Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC). Company Calendar Last Earnings8/12/2026Today9/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BCDA's financial health is in the Red zone, according to TradeSmith. BCDA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCDA CIK925741 Webwww.biocardia.com Phone(650) 226-0123Fax310-861-5299Employees21Year Founded2002Price Target and Rating Average Price Target for BioCardia$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+2,281.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-569.36% Return on Assets-183.15% Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.09 Sales & Book Value Annual Sales$60 thousand Price / Sales264.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book13.13Miscellaneous Outstanding Shares15,140,000Free Float12,505,000Market Cap$15.90 million OptionableOptionable Beta0.55 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BCDA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredThe REAL Reason 2,000 Missiles Rained on IranTwo private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...Behind the Markets | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
